Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Notes Payables: 2016-2018

Historic Notes Payables for Tg Therapeutics (TGTX) over the last 3 years, with Dec 2018 value amounting to $67,000.

  • Tg Therapeutics' Notes Payables fell 47.66% to $67,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $67,000, marking a year-over-year decrease of 47.66%. This contributed to the annual value of $67,000 for FY2018, which is 47.66% down from last year.
  • According to the latest figures from FY2018, Tg Therapeutics' Notes Payables is $67,000, which was down 47.66% from $128,000 recorded in FY2017.
  • In the past 5 years, Tg Therapeutics' Notes Payables registered a high of $128,000 during FY2017, and its lowest value of $67,000 during FY2018.
  • Its 3-year average for Notes Payables is $87,958, with a median of $68,875 in 2016.
  • Per our database at Business Quant, Tg Therapeutics' Notes Payables skyrocketed by 85.84% in 2017 and then crashed by 47.66% in 2018.
  • Yearly analysis of 3 years shows Tg Therapeutics' Notes Payables stood at $68,875 in 2016, then surged by 85.84% to $128,000 in 2017, then tumbled by 47.66% to $67,000 in 2018.